Bio & Pharma
OliX's hair loss treatment candidate approved for clinical trial in Australia
The S.Korean company plans to evaluate the safety of OLX72021 in Australia with androgenetic alopecia
By Mar 10, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
South Korea sets sights on fostering EDA tech to win HBM chip war
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![OliX's hair loss treatment candidate approved for clinical trial in Australia](https://www.kedglobal.com/data/ked/image/2023/03/10/ked202303100002.399x.0.jpg)
South Korea's OliX Pharmaceuticals has received approval from Australia's Human Research Ethics Committees (HREC) to plan a phase 1 clinical trial of OLX72021, a candidate for the treatment of male pattern hair loss.
OLX72021 is a treatment that inhibits the activity of hormones that cause male hair loss, and the effect lasted for more than three weeks in animal tests.
OliX plans to evaluate the safety and tolerability of OLX72021 at a clinical site in Australia for up to 30 healthy men with androgenetic alopecia, a disease in which hair loss begins while gradually thinning the hair from the top of the head.
"Interest in hair loss treatment is very high across the world, so we expect quick patient enlistment and administration," said Lee Dong-ki, CEO of OliX Pharmaceuticals. The clinical trial is scheduled to continue until May next year.
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Bio & PharmaPrestige Biopharma submits clinical trial plan in Australia
Feb 03, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaDaewoong Pharma's botulinum toxin Nabota wins approval from Australia
Jan 26, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaInventage Lab launches clinical trials for addiction treatment in Australia
Jan 26, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN